BACKGROUND: The monoclonal antibody cetuximab (IMC-225, Erbitux) inhibits epidermal growth factor receptor (EGFR) signaling and has been approved for metastatic colon cancer therapy. However, to achieve effective titers, passive antibody therapies must be repeatedly administered over long periods. To overcome this limitation, we aimed to generate a vaccine inducing continuously available "cetuximab-like" antibodies in vivo using the mimotope approach. METHODS: We used the phage display technique to identify four peptides structurally mimicking the cetuximab epitope. We coupled two of these peptides to an immunogenic carrier protein, and we vaccinated four groups (n = 8) of BALB/c mice intraperitoneally with 10 microg of the mimotope conjugates, a control peptide conjugate, or the carrier protein alone. We assessed antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity mediated by the induced antibodies against EGFR-overexpressing human A431 carcinoma cells. We then tested receptor internalization capacity of the induced antibodies with fluorescently labeled EGFR, and we assayed their growth inhibitory potential toward A431 cells with a [3H]thymidine proliferation assay. RESULTS: Mimotope-induced antibodies recognized EGFR, and both types of antibody-mediated cytotoxic effects were elicited by these antibodies. In both cellular cytotoxicity assays, the mimotope-induced antibodies exhibited specific lysis of more than 50%. The induced antibodies caused internalization of the receptor from the cell surface into endocytic vesicles and inhibited growth of EGFR-expressing cells to a similar extent as cetuximab [67% (95% confidence interval {CI} = 55% to 79%) and 69% (95% CI = 55% to 84%), respectively]. CONCLUSIONS: Epitope-specific immunization is feasible for active anti-EGFR immunotherapy. The in vitro biologic features of mimotope-induced antibodies are similar to those of the monoclonal antibody cetuximab.
BACKGROUND: The monoclonal antibody cetuximab (IMC-225, Erbitux) inhibits epidermal growth factor receptor (EGFR) signaling and has been approved for metastatic colon cancer therapy. However, to achieve effective titers, passive antibody therapies must be repeatedly administered over long periods. To overcome this limitation, we aimed to generate a vaccine inducing continuously available "cetuximab-like" antibodies in vivo using the mimotope approach. METHODS: We used the phage display technique to identify four peptides structurally mimicking the cetuximab epitope. We coupled two of these peptides to an immunogenic carrier protein, and we vaccinated four groups (n = 8) of BALB/c mice intraperitoneally with 10 microg of the mimotope conjugates, a control peptide conjugate, or the carrier protein alone. We assessed antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity mediated by the induced antibodies against EGFR-overexpressing human A431 carcinoma cells. We then tested receptor internalization capacity of the induced antibodies with fluorescently labeled EGFR, and we assayed their growth inhibitory potential toward A431 cells with a [3H]thymidine proliferation assay. RESULTS: Mimotope-induced antibodies recognized EGFR, and both types of antibody-mediated cytotoxic effects were elicited by these antibodies. In both cellular cytotoxicity assays, the mimotope-induced antibodies exhibited specific lysis of more than 50%. The induced antibodies caused internalization of the receptor from the cell surface into endocytic vesicles and inhibited growth of EGFR-expressing cells to a similar extent as cetuximab [67% (95% confidence interval {CI} = 55% to 79%) and 69% (95% CI = 55% to 84%), respectively]. CONCLUSIONS: Epitope-specific immunization is feasible for active anti-EGFR immunotherapy. The in vitro biologic features of mimotope-induced antibodies are similar to those of the monoclonal antibody cetuximab.
Authors: E Jensen-Jarolim; G Achatz; M C Turner; S Karagiannis; F Legrand; M Capron; M L Penichet; J A Rodríguez; A G Siccardi; L Vangelista; A B Riemer; H Gould Journal: Allergy Date: 2008-07-26 Impact factor: 13.146
Authors: Joshua M Donaldson; Cindy Zer; Kendra N Avery; Krzysztof P Bzymek; David A Horne; John C Williams Journal: Proc Natl Acad Sci U S A Date: 2013-10-07 Impact factor: 11.205
Authors: Franca Maria Tuccillo; Camillo Palmieri; Giuseppe Fiume; Annamaria de Laurentiis; Marco Schiavone; Cristina Falcone; Enrico Iaccino; Ricciarda Galandrini; Cristina Capuano; Angela Santoni; Francesco Paolo D'Armiento; Claudio Arra; Antonio Barbieri; Fabrizio Dal Piaz; David Venzon; Patrizia Bonelli; Franco Maria Buonaguro; Iris Scala; Massimo Mallardo; Ileana Quinto; Giuseppe Scala Journal: Mol Cancer Ther Date: 2013-12-19 Impact factor: 6.261
Authors: Esther J Witsch; Georg Mahlknecht; Jean Wakim; Rotem Sertchook; Erez Bublil; Yosef Yarden; Michael Sela Journal: Int Immunol Date: 2011-05-19 Impact factor: 4.823
Authors: Hester A Doyle; Raymond A Koski; Nathalie Bonafé; Ross A Bruck; Stephanie M Tagliatela; Renelle J Gee; Mark J Mamula Journal: Cancer Immunol Immunother Date: 2018-07-28 Impact factor: 6.968
Authors: Joshua M Donaldson; Csaba Kari; Ruben C Fragoso; Ulrich Rodeck; John C Williams Journal: Cancer Biol Ther Date: 2009-11-07 Impact factor: 4.742